Abstract
Introduction: Ehlers-Danlos syndromes (EDS) represent a group of heritable connective tissue disorders characterized by skin hyperelasticity, joint hypermobility and generalized tissue fragility. Many patients remain undiagnosed years after initial symptoms and an accurate diagnosis is difficult despite all efforts. Currently, Germany lacks a patient registry and a specialized EDS centre. Methods: In early 2020, a dermatological-orthopaedic EDS outpatient service was established at the University Hospital of Cologne. Medical records of all patients presenting in 2020 were retrospectively analysed. Results: Forty-three adults were examined. Fifteen patients were diagnosed with EDS (different types), 13 with hypermobility spectrum disorder, and 1 with likely Loeys-Dietz syndrome (LDS) based on patient history and a suspicious variant in the gene TGFBR1. Excluding hypermobile EDS (6 patients), molecular confirmation was achieved in a total of 4 of 9 patients. The combination of symptomatic generalized hypermobility and skin manifestations was diagnostic in more than two-thirds of the EDS patients. Arterial involvement (aneurysms, dissection and rupture) and distinctive cutaneous signs (thin translucent skin with haematomas) indicated vascular EDS and LDS in altogether 3 patients. Conclusion: With the present analysis, we discuss our diagnostic approach in patients with a suspected diagnosis of EDS in order to raise awareness of this rare group of genodermatoses and review recent developments in EDS nosology.
References
1.
Malfait
F
, Castori
M
, Francomano
CA
, Giunta
C
, Kosho
T
, Byers
PH
. The Ehlers-Danlos syndromes
. Nat Rev Dis Primers
. 2020
;6
(1
):64
. 2.
Malfait
F
, Francomano
C
, Byers
P
, Belmont
J
, Berglund
B
, Black
J
, et al. The 2017 International classification of the Ehlers-Danlos syndromes
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):8
–26
. 3.
Tinkle
B
, Castori
M
, Berglund
B
, Cohen
H
, Grahame
R
, Kazkaz
H
, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): clinical description and natural history
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):48
–69
. 4.
Castori
M
, Tinkle
B
, Levy
H
, Grahame
R
, Malfait
F
, Hakim
A
. A framework for the classification of joint hypermobility and related conditions
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):148
–57
. 5.
Colombi
M
, Dordoni
C
, Cinquina
V
, Venturini
M
, Ritelli
M
. A classical Ehlers-Danlos syndrome family with incomplete presentation diagnosed by molecular testing
. Eur J Med Genet
. 2018
;61
(1
):17
–20
. 6.
Shalhub
S
, Byers
PH
, Hicks
KL
, Coleman
DM
, Davis
FM
, De Caridi
G
, et al. A multi-institutional experience in vascular Ehlers-Danlos syndrome diagnosis
. J Vasc Surg
. 2020
;71
(1
):149
–57
. 7.
Castori
M
, Hakim
A
. Contemporary approach to joint hypermobility and related disorders
. Curr Opin Pediatr
. 2017
;29
(6
):640
–9
. 8.
Remvig
L
, Jensen
DV
, Ward
RC
. Are diagnostic criteria for general joint hypermobility and benign joint hypermobility syndrome based on reproducible and valid tests? A review of the literature
. J Rheumatol
. 2007
;34
(4
):798
–803
.9.
Juul-Kristensen
B
, Schmedling
K
, Rombaut
L
, Lund
H
, Engelbert
RHH
. Measurement properties of clinical assessment methods for classifying generalized joint hypermobility-A systematic review
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):116
–47
. 10.
Remvig
L
, Jensen
DV
, Ward
RC
. Epidemiology of general joint hypermobility and basis for the proposed criteria for benign joint hypermobility syndrome: review of the literature
. J Rheumatol
. 2007
;34
(4
):804
–9
.11.
Parapia
LA
, Jackson
C
. Ehlers-Danlos syndrome: a historical review
. BJH
. 2008
;141
(1
):32
–5
. 12.
Proske
S
, Hartschuh
W
, Enk
A
, Hausser
I
. Ehlers-Danlos syndrome: 20 years experience with diagnosis and classification
. J Dtsch Dermatol Ges
. 2006
;4
(4
):308
–18
. 13.
Angwin
C
, Ghali
N
, Baker
D
, Brady
AF
, Pope
FM
, Vandersteen
A
, et al. Electron microscopy in the diagnosis of Ehlers-Danlos syndromes: correlation with clinical and genetic investigations
. Br J Dermatol
. 2020
;182
(3
):698
–707
. 14.
Ritelli
M
, Chiarelli
N
, Cinquina
V
, Zoppi
N
, Bertini
V
, Venturini
M
, et al. RNA-seq of dermal fibroblasts from patients with hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorders supports their categorization as a single entity with involvement of extracellular Matrix degrading and proinflammatory pathomechanisms
. Cells
. 2022
;11
(24
):4040
. 15.
Byers
PH
, Belmont
J
, Black
J
, De Backer
J
, Frank
M
, Jeunemaitre
X
, et al. Diagnosis, natural history, and management in vascular Ehlers-Danlos syndrome
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):40
–7
. 16.
Brady
AF
, Demirdas
S
, Fournel-Gigleux
S
, Ghali
N
, Giunta
C
, Kapferer-Seebacher
I
, et al. The Ehlers-Danlos syndromes, rare types
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):70
–115
. 17.
Colombi
M
, Dordoni
C
, Chiarelli
N
, Ritelli
M
. Differential diagnosis and diagnostic flow chart of joint hypermobility syndrome/ehlers-danlos syndrome hypermobility type compared to other heritable connective tissue disorders
. Am J Med Genet C Semin Med Genet
. 2015
;169C
(1
):6
–22
. 18.
Meester
JAN
, Verstraeten
A
, Schepers
D
, Alaerts
M
, Van Laer
L
, Loeys
BL
. Differences in manifestations of Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome
. Ann Cardiothorac Surg
. 2017
;6
:582
–94
. 19.
McGillis
L
, Mittal
N
, Santa Mina
D
, So
J
, Soowamber
M
, Weinrib
A
, et al. Utilization of the 2017 diagnostic criteria for hEDS by the Toronto GoodHope Ehlers-Danlos syndrome clinic: a retrospective review
. Am J Med Genet A
. 2020
;182
(3
):484
–92
. 20.
Malek
S
, Reinhold
EJ
, Pearce
GS
. The Beighton Score as a measure of generalised joint hypermobility
. Rheumatol Int
. 2021
;41
(10
):1707
–16
. 21.
Aubry-Rozier
B
, Schwitzguebel
A
, Valerio
F
, Tanniger
J
, Paquier
C
, Berna
C
, et al. Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different
. Rheumatol Int
. 2021
;41
(10
):1785
–94
. 22.
Available from: https://www.ehlers-danlos.com/hedge/
24.
Copetti
M
, Morlino
S
, Colombi
M
, Grammatico
P
, Fontana
A
, Castori
M
. Severity classes in adults with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders: a pilot study of 105 Italian patients
. Rheumatol
. 2019
;58
(10
):1722
–30
. 25.
Cederlöf
M
, Larsson
H
, Lichtenstein
P
, Almqvist
C
, Serlachius
E
, Ludvigsson
JF
. Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers-Danlos syndrome or hypermobility syndrome and their siblings
. BMC Psychiatry
. 2016
;16
:207
. 26.
Choudhary
A
, Fikree
A
, Aziz
Q
. Overlap between irritable bowel syndrome and hypermobile Ehlers-Danlos syndrome: an unexplored clinical phenotype
. Am J Med Genet C Semin Med Genet
. 2021
;187
(4
):561
–9
. 27.
Roma
M
, Marden
CL
, De Wandele
I
, Francomano
CA
, Rowe
PC
. Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome
. Auton Neurosci
. 2018
;215
:89
–96
. 28.
Hakim
A
, De Wandele
I
, O'Callaghan
C
, Pocinki
A
, Rowe
P
. Chronic fatigue in Ehlers-Danlos syndrome-Hypermobile type
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):175
–80
. 29.
Hakim
A
, Tinkle
B
, Francomano
C
. Ehlers-Danlos syndromes, hypermobility spectrum disorders, and associated co-morbidities: reports from EDS ECHO
. Am J Med Genet C Semin Med Genet
. 2021
;187
(4
):413
–5
. 30.
Seneviratne
SL
, Maitland
A
, Afrin
L
. Mast cell disorders in Ehlers-Danlos syndrome
. Am J Med Genet C Semin Med Genet
. 2017
;175
(1
):226
–36
. 31.
Vengoechea
J
. In reply to “mast cell disorders in ehlers-danlos syndrome”
. Am J Med Genet A
. 2018
;176
(1
):250
. 32.
Wasim
S
, Suddaby
JS
, Parikh
M
, Leylachian
S
, Ho
B
, Guerin
A
, et al. Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and hypermobility spectrum disorders: a retrospective study
. Rheumatol Int
. 2019
;39
(7
):1241
–8
. 33.
Csecs
J
, Dowell
N
, Savage
G
, Iodice
V
, Mathias
CJ
, Critchley
HD
, et al. Variant connective tissue (joint hypermobility) and dysautonomia are associated with multimorbidity at the intersection between physical and psychological health
. Am J Med Genet C Semin Med Genet
. 2021
;187
(4
):500
–9
. 34.
Kucharik
AH
, Chang
C
. The relationship between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS)
. Clin Rev Allergy Immunol
. 2020
;58
(3
):273
–97
. 35.
Tai
FWD
, Palsson
OS
, Lam
CY
, Whitehead
WE
, Sperber
AD
, Tornblom
H
, et al. Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome
. Neurogastroenterol Motil
. 2020
;32
(12
):e13975
. © 2024 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2024
You do not currently have access to this content.
